
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Feb 07, 2026 03:05 am UTC| Governance Health Business
The U.S. Food and Drug Administration (FDA) announced on Friday that it will take enforcement action against telehealth provider Hims Hers over its $49 weight-loss pill, escalating scrutiny of compounded GLP-1 drugs sold...

TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Feb 07, 2026 02:44 am UTC| Health Politics
President Donald Trump has launched a new prescription drug pricing website, TrumpRx.gov, aiming to showcase his administrations efforts to reduce drug costs in the United States. The website focuses heavily on negotiated...

Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition
Feb 04, 2026 02:05 am UTC| Business Health
Novo Nordisk, the maker of blockbuster weight-loss drug Wegovy, has warned that profits and sales could fall by as much as 13% this year, marking its first potential decline in years. The Danish pharmaceutical giant cited...

RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash
Jan 29, 2026 01:35 am UTC| Health Governance
U.S. Health Secretary Robert F. Kennedy Jr. has reshaped national autism policy by appointing an entirely new slate of 21 members to the Interagency Autism Coordinating Committee (IACC), a federal panel that provides...

Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
Jan 23, 2026 07:26 am UTC| Business Health
Sanofi (EPA: SASY) has announced encouraging late-stage clinical trial results for its investigational drug amlitelimab, reinforcing its potential as a new treatment option for patients with moderate to severe eczema. The...

U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Jan 22, 2026 06:25 am UTC| Governance Health Business
Sweeping changes to U.S. vaccine policy under Health Secretary Robert F. Kennedy Jr. are creating uncertainty across the pharmaceutical sector, dampening investor confidence and raising concerns among vaccine...

FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns
Jan 16, 2026 02:45 am UTC| Governance Health
The U.S. Food and Drug Administration has delayed reviews of several drugs selected for the Trump administrations new fast-track approval initiative after internal reviewers raised concerns about safety, efficacy, and...